Alvotech (ALVO) Revenue Surges 21% Year-Over-Year in 2025 [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
earnings results, delivering revenues of $593 million for the year, representing a 21% year-over-year growth and greatly surpassing analyst projections with Q4 EPS of $0.03 versus a predicted loss of $0.0833. Alvotech (NASDAQ:ALVO) has revealed 15 distinct programs aimed at key biologics, such as Xolair, Entyvio, Eylea HD, and Keytruda, with over 30 biosimilar candidates in development. For these reported candidates, the total addressable market is more than $185 billion. Despite barriers to regulation in the US, Alvotech's on-market products have managed to gain traction in overseas markets. The company's biosimilar of Humira, AVT02, profited from the originator's dwindling US market share, which declined from 70% to around 45% by the end of 2025. On the manufacturing side, Alvotech (NASDAQ:ALVO) is extending its perfusion manufacturing capacity in Reykjavik by adding a third medical component and an additional product production unit. ?Alvotech (NASDAQ:ALVO) is a biotechnolo
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech (ALVO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALVO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Teva receives FDA approval for Prolia biosimilar [Yahoo! Finance]Yahoo! Finance
- Alvotech Files Annual Report with the SECGlobeNewswire
- Alvotech (ALVO) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALVO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
- Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position [Yahoo! Finance]Yahoo! Finance
ALVO
Earnings
- 11/12/25 - Beat
ALVO
Sec Filings
- 3/31/26 - Form 20-F
- 3/19/26 - Form 6-K
- 3/12/26 - Form SCHEDULE
- ALVO's page on the SEC website